Novo Nordisk (NYSE:NVO) shares jumped over 11% in premarket trading on Thursday following disappointing data on Eli Lilly’s oral obesity drug orforglipron, which raised concerns over its efficacy and ...

Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said.